All nine subjects of phase 1 injected without any serious adverse events.
Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
Tolebrutinib was generally well tolerated by all subjects across all study arms.
IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.
The FDA’s animal testing requirement will be decreased, modified, or potentially replaced utilizing a variety of methodologies.
By inserting a complete gene, the technique provides a one-step solution that overcomes the limitations of CRISPR gene editing technology.
Colossal Biosciences, the business seeking to make extinction optional, has resurrected a prehistoric predator best known for its role in Game of Thrones. Approximately 20 distinctive genetic variations related to distinct dire wolf features were discovered. These characteristics include greater stature, a more robust body, broader heads, stronger jaws, and […]
A one-size-fits-all strategy to protein purification is no longer practicable, given the development and transformation of the mAb market, notably the recent rapid emergence of biosimilars. To solve this, Cytiva created two new protein A resins, the MabSelect SuRe 70 and the MabSelect PrismA X. The different stages of drug […]
Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.
IgG4-RD can arise in various organs, causing fibrosis and irreversible organ damage. Understanding how organ damage occurs is key to making an accurate diagnosis of IgG4-RD.
